Using genetics to guide warfarin dosing after hip, knee replacement

September 26, 2017

Among patients undergoing hip or knee replacement and treated with the blood thinner warfarin, customizing dosing to a patient's genetic and clinical profile resulted in the prevention of more adverse outcomes than clinically-guided dosing, according to a study published by JAMA.

For at least the last 10 years, warfarin use has accounted for more medication-related emergency department visits among older patients than any other drug. Warfarin dose requirements vary widely among individuals because of common genetic variants. Because knowledge of a patient's genotype should lead to more accurate warfarin initiation and a reduction in adverse events, the product label for warfarin (Coumadin and others) has encouraged genotype-guided dosing since 2007. However, multicenter studies of genotype-guided dosing of oral vitamin K antagonists have had mixed results. Thus, it was unclear whether genotype-guided dosing could improve the safety of warfarin initiation.

Brian F. Gage, M.D., M.Sc., of Washington University in St. Louis, and colleagues randomly assigned patients ages 65 years or older initiating warfarin for elective hip or knee replacement to genotype-guided or clinically-guided warfarin dosing on days 1 through 11 of therapy and to a target international normalized ratio (INR) of either 1.8 or 2.5. Patients were genotyped for certain genetic variants.

Among 1,650 randomized patients, 97 percent received at least 1 dose of warfarin therapy and completed the trial (n = 808 in genotype-guided group vs n = 789 in clinically-guided group). A total of 87 patients (10.8 percent) in the genotype-guided group vs 116 patients (14.7 percent) in the clinically guided warfarin dosing group met at least one of the end points (major bleeding, INR of 4 or greater, venous thromboembolism or death). The numbers of individual events in the genotype-guided group vs the clinically guided group were 2 vs 8 for major bleeding, 56 vs 77 for INR of 4 or greater, and 33 vs 38 for venous thromboembolism; there were no deaths.

The study notes some limitations, including that the benefits of genotype-guided dosing may differ when applied to patients of other ages or to general clinical practice.

"Further research is needed to determine the cost-effectiveness of personalized warfarin dosing," the authors write.
For more details and to read the full study, please visit the For The Media website.


Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Knee Replacement Articles from Brightsurf:

Study compares racial disparities in unilateral versus bilateral knee replacement
Analyzing data from the NIS - Healthcare Cost and Utilization Project database, researchers at Hospital for Special Surgery (HSS) found that African Americans were much less likely to undergo bilateral knee replacement compared to white patients.

Steroid injections do not hasten the need for knee replacement
New research shows that corticosteroid injections for knee OA treatment do not hasten a patient's progression to a total knee replacement when compared with hyaluronic acid injections.

Warfarin use significantly increases risk of knee and hip replacement in people with OA
New research shows that use of warfarin is associated with a significantly greater risk of knee and hip replacements in patients with OA.

Younger knee replacement patients more likely to require reoperation
Knee replacement surgery, also known as total knee arthroplasty (TKA), is increasing among patients 65 and younger.

Osteoarthritis: Conservative therapy delays need for knee and hip joint replacement surgery
With implementation of conservative treatment methods like physiotherapy and individually tailored, adjusted exercises, quality of osteoarthritis care can improve and patients can delay the need for an artificial hip or knee joint.

Changes in opioid use after hip, knee replacement
Researchers looked at changes in opioid prescribing rates and level of pain control in patients who had hip or knee replacement in the U.S. from 2014 to 2017.

Knee replacement timing is all wrong for most patients
The timing of knee replacement surgery is critical to optimize its benefit.

Study: 'Pre-habilitation' by peer coaches before knee replacement may improve outcomes
HSS researchers launched a study to see if a 'pre-habilitation'' program - counseling by a peer coach who has already had knee replacement - could empower and inform patients scheduled for the surgery and lead to better outcomes.

Study finds racial variation in post-op care after knee replacement surgery
A large study analyzing 107,000 knee replacement surgeries found that African Americans were significantly more likely than white patients to be discharged to an inpatient rehabilitation or skilled nursing facility rather than home care after the procedure.

Race and poverty not risk factors for total knee replacement revision or failure
In a new study published in Arthritis Care & Research, HSS investigators found race and poverty are not risk factors for total knee replacement revision or failure at a high-volume orthopedic hospital.

Read More: Knee Replacement News and Knee Replacement Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to